The New York State Department of Health (NYSDOH) said the newly authorized oral antiviral treatments, including Paxlovid (Pfizer) and molnupiravir (Merck), are in “limited supply will require providers to prioritize treatment for patients at highest risk for severe COVID-19 until more product becomes available.”
The NYSDOH list being non-white “should be considered a risk factor, as long-standing systemic health and social inequities have contributed to an increased risk of severe illness and death from Covid-19.”
Nicholas A. Christakis tweeted regarding the racist allocation criteria:
“How is the race or ethnicity of a patient a legitimate criterion for the allocation of scarce clinical resources (like drugs or hospital beds) by a government entity in 2021 in the USA? And how could this even be constitutional?”
Tell us your thoughts in the Facebook post and share this with your friends.
